Nanox, an innovative medical imaging technology company, announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,826,530 ordinary shares (“Common Stock”) in a registered direct offering. The offering is expected to result in gross proceeds of approximately $15 million, before deducting offering expenses. The closing of the offering is expected to occur on or about November 25, 2025, subject to the satisfaction of customary closing conditions.
Related: Cordance Medical raises $8M seed for focused ultrasound used in brain treatment
The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
“This successful capital raise further strengthens our balance sheet and accelerates our key growth initiatives including advancing the Company’s technologies, expanding our market presence, and enhancing our AI infrastructure,” said Erez Meltzer, Chief Executive Officer of Nanox. “As we scale deployments and expand our capabilities, we expect these efforts to reinforce our growth trajectory while advancing our mission to make high-quality medical imaging more accessible worldwide.”
Titan Partners Group, a division of American Capital Partners, is acting as the sole placement agent for the offering.
This offering is being made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-271688) that was filed by Nanox with the U.S. Securities and Exchange Commission (the “SEC”), under the Securities Act of 1933, as amended (the “Securities Act”), and became effective on May 5, 2023, as amended. The proposed offering of these securities is being made only by means of a prospectus and a related prospectus supplement describing the terms of the offering, which will be filed with the SEC and, once filed, will be available on the SEC’s website located at http://www.sec.gov. Additionally, when available, electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, from Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 49th Floor, New York, NY 10007, or by telephone at 929-833-1246, or by email at prospectus@titanpartnersgrp.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities or any other securities, nor shall there be any offer, solicitation or sale of these securities or any other securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
